Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.2% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price dropped 6.2% during trading on Wednesday following insider selling activity. The company traded as low as $28.98 and last traded at $28.59. Approximately 9,500,766 shares changed hands during trading, a decline of 39% from the average daily volume of 15,661,397 shares. The stock had previously closed at $30.47.

Specifically, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the transaction, the chief financial officer directly owned 91,617 shares in the company, valued at $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Analyst Ratings Changes

Several brokerages have recently issued reports on HIMS. BTIG Research restated a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Bank of America upped their price objective on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $44.54.

Hims & Hers Health Price Performance

The company has a market cap of $6.74 billion, a P/E ratio of 54.86, a PEG ratio of 5.17 and a beta of 2.37. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm’s 50-day moving average is $34.95 and its two-hundred day moving average is $45.08.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has authorized a share buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. Farther Finance Advisors LLC raised its stake in shares of Hims & Hers Health by 5.5% in the fourth quarter. Farther Finance Advisors LLC now owns 20,057 shares of the company’s stock valued at $651,000 after acquiring an additional 1,052 shares in the last quarter. Cura Wealth Advisors LLC grew its holdings in shares of Hims & Hers Health by 8.5% during the fourth quarter. Cura Wealth Advisors LLC now owns 6,512 shares of the company’s stock worth $211,000 after purchasing an additional 512 shares during the last quarter. State of Alaska Department of Revenue increased its position in Hims & Hers Health by 63.6% during the fourth quarter. State of Alaska Department of Revenue now owns 37,029 shares of the company’s stock worth $1,202,000 after buying an additional 14,396 shares during the period. Diligent Investors LLC grew its position in Hims & Hers Health by 5.1% during the 4th quarter. Diligent Investors LLC now owns 13,198 shares of the company’s stock worth $429,000 after purchasing an additional 640 shares during the last quarter. Finally, Ritholtz Wealth Management acquired a new position in Hims & Hers Health in the 4th quarter valued at about $248,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.